|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Cell Differentiation, Institute
of Molecular Embryology and Genetics, Kumamoto University, Japan;
Molecular/Cancer Biology Laboratory, Haartman Institute, PL21,
University of Helsinki, Helsinki, Finland; and the Department of
Medical Biophysics, University of Toronto, Ontario, Canada.
Signaling by vascular endothelial growth factors (VEGFs) through
VEGF receptors (VEGFRs) plays important roles in vascular development
and hematopoiesis. The authors analyzed the function of VEGF-C
signaling through both VEGFR-2 and VEGFR-3 in vasculoangiogenesis and
hematopoiesis using a coculture of para-aortic splanchnopleural mesoderm (P-Sp) explants from mouse embryos with stromal cells (OP9).
Vasculogenesis and angiogenesis were evaluated by the extent of
vascular bed and network formation, respectively. Addition of VEGF-C to
the P-Sp culture enhanced vascular bed formation and suppressed
definitive hematopoiesis. Both vascular bed and network formations were
completely suppressed by addition of soluble VEGFR-1-Fc competitor
protein. Formation of vascular beds but not networks could be rescued
by VEGF-C in the presence of the competitor, while both were rescued by
VEGF-A. VEGFR-3-deficient embryos show the abnormal vasculature and
severe anemia. Consistent with these in vivo findings, vascular bed
formation in the P-Sp from the VEGFR-3-deficient embryos was enhanced
to that in wild-type or heterozygous embryos, and hematopoiesis was
severely suppressed. When VEGFR-3-Fc chimeric protein was added to
trap endogenous VEGF-C in the P-Sp culture of the VEGFR-3-deficient
embryos, vascular bed formation was suppressed and hematopoiesis was
partially rescued. These results demonstrate that because VEGF-C
signaling through VEGFR-2 works synergistically with
VEGF-A, the binding of VEGF-C to VEGFR-3 consequently regulates
VEGFR-2 signaling. In VEGFR-3-deficient embryos, an excess of VEGF-C
signals through VEGFR-2 induced the disturbance of vasculogenesis and
hematopoiesis during embryogenesis. This indicates that elaborated
control through VEGFR-3 signaling is critical in vasculoangiogenesis
and hematopoiesis.
(Blood. 2000;96:3793-3800) Embryonic development of blood vessels from
endothelial cells consists of vasculogenesis and angiogenesis.
Vasculogenesis is a process by which vascular endothelial cell
precursors, angioblasts, proliferate and differentiate to form
primitive blood vessels. Vascular network formation, or angiogenesis,
subsequently occurs as a result of sprouting or branching from
pre-existing vessels.1,2 Vasculoangiogenesis is regulated
by paracrine signals, many of which are protein ligands that bind to
and modulate the activity of transmembrane receptor tyrosine
kinases.3-5 Among the vasculoangiogenic factors, vascular
endothelial growth factor (VEGF) family members and their receptors are
known to be critical for vasculoangiogenesis.6
The VEGF receptor (VEGFR) family consists of 3 members: VEGFR-1
(Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). At least 5 ligands
(VEGF-A, VEGF-B, VEGF-C, VEGF-D, and VEGF-E) and placenta growth factor
(PlGF) bind to 1 or 2 of these receptors. VEGF-A stimulates vascular
endothelial cells through both VEGFR-1 and VEGFR-23;
however, the roles of VEGFR-1 and VEGFR-2 differ significantly. VEGFR-1-deficient mice show aberrant vascular
development,7 whereas VEGFR-2-deficient mice show severe
defects in both vasculogenesis and hematopoiesis.8 VEGF-A
is also indispensable for development of blood vessels: mice hemizygous
for VEGF-A die from abnormal vasculature.9,10 VEGF-B binds
to only VEGFR-1 and may be involved in regulation of extracellular
matrix degradation, cell adhesion, and migration.11 VEGF-C
and VEGF-D do not bind to VEGFR-1, although both are ligands for
VEGFR-2 and VEGFR-3. Both VEGF-C and VEGF-D primarily affect
development of lymphatic vasculature through activation of
VEGFR-3.12-14 VEGF-E, which is a ligand for VEGFR-2, has
been identified as a gene encoded by the parapoxvirus Orf virus. VEGF-E
is expressed as the native protein in mammalian cells. VEGF-E and
VEGF-A possess similar bioactivities: both factors stimulate the
release of tissue factor and enhance the proliferation, chemotaxis, and
sprouting of cultured vascular endothelial cells in vitro and in
vivo.15
VEGF-C, which was identified as a ligand for VEGFR-3 and
VEGFR-2,12 is expressed in endothelial cell precursors on
embryonic day 8.5 (E8.5) in mouse. VEGFR-3 is later expressed in the
lymphatic endothelium,16 indicating that it may play a
role in the lymphatic vasculature.13 Transgenic mice
overexpressing VEGF-C in the skin show atrophic changes in the dermis,
where connective tissue is replaced by large lymphatic
vessels.17 Thus, endothelial proliferation induced by
VEGF-C leads to hyperplasia of the superficial lymphatic network
but does not appear to induce sprouting of new vessels after birth. On
the other hand, VEGFR-3-deficient mice die by E10.5. Although
vasculogenesis and angiogenesis occur, large vessels are abnormally
organized with defective lumens before the emergence of the lymphatic
vessels.18 These results suggest that VEGF-C plays a
critical role in proliferation and differentiation of vascular
endothelial cells at an early embryonic stage. It is not known whether
the biologic function of VEGF-C is the same as that of VEGF-A; nor has
it been shown whether VEGFR-2 and VEGFR-3 transduce the same signals
upon binding of VEGF-C.
We have recently established a coculture system consisting of
para-aortic splanchnopleural mesoderm (P-Sp) explants and OP9 stromal
cells.19 This culture system is used to assay both
vasculoangiogenesis and hematopoiesis. In this study, we analyzed the
biologic function of VEGF-C signaling through VEGFR-2 and VEGFR-3 using
the P-Sp cultures from either wild-type or VEGFR-3-deficient mice in
various conditions. Using this system, functional differences in VEGF-C signaling through VEGFR-2 and VEGFR-3 were detected.
Reagents and animals
LacZ and immunohistochemistry staining
Production of recombinant fusion protein We constructed recombinant fusion genes containing the extracellular domain of murine VEGFR-1 and VEGFR-3 and the Fc part of human immunoglobulin as previously described.22,23 VEGFR-1-Fc and VEGFR-3-Fc fusion proteins were obtained from the serum-free conditioned medium of COS7 cells transfected with these genes24 and purified over protein-A columns (Affi-Gel protein A; Bio-Rad, Hercules, CA). Coomassie brilliant blue staining of sodium dodecyl sulfate-polyacrylamide gel electrophoresis was used to assess purity and disulfide-linked dimerization.FACS-gal staining Fluorescence-activated cell sorter (FACS)-gal staining was carried out essentially as described.25 To reduce background fluorescence after dissection, tissues were incubated in Dulbecco modified Eagle medium (DMEM)/fetal calf serum (FCS) containing 3 mmol/L chloroquine for 30 minutes at 37°C, with 5% CO2. Following 2 rinses in PBS, tissues were incubated with dispase I (Boehringer Mannheim, Mannheim, Germany) for 10 minutes at room temperature. Dispersed embryo tissue was drawn through a 23G needle and treated to produce a single-cell suspension. After washing once in DMEM/FCS, cells were counted using a hemocytometer. The cells were then loaded with fluorescein di- -D-galactopyranoside (FDG) (Molecular Probes, Eugene,
OR) by osmotic shock. After the cells had been allowed to equilibrate
at 37°C for 10 minutes, an equal volume of prewarmed 2 mmol/L FDG in
sterile water was rapidly mixed with the cell suspension. After 1 minute of incubation at 37°C, FDG loading was stopped by adding 2 mL
ice-cold staining media, and the tube was placed on ice for 2 hours to
allow enzymatic conversion of FDG to fluorescein. After conversion, the
cells were stained with monoclonal antibodies. The monoclonal
antibodies used in imunofluorescence were anti-Flk-1/VEGFR-2 (AVAS12)
and anti-PECAM-1/CD31 (MEC13.3). These monoclonal antibodies were
purified and conjugated with phycoerythrin or biotin. Biotinylated
antibodies were visualized with allophycocyanin-conjugated streptavidin
(Caltag Laboratories, Burlingame, CA). The stained cells were analyzed
by a FACSCalibur or a FACSvantage (Becton Dickinson, San Jose, CA).
In vitro culture of P-Sp and hematopoietic progenitors The stromal cell line, OP9,26 was maintained in -modified minimum essential media (Gibco BRL, Gaithersburg, MD)
supplemented with 20% FCS (JRH Bioscience, Lenexa, KS). P-Sp culture
conditions were as described.19 In brief, P-Sp explants of
E9.5 embryos were cultured on OP9 stromal cells in RPMI1640 (Gibco BRL)
with 10% FCS and 10 5-mol/L 2ME (Sigma, St Louis, MO)
supplemented with interleukin (IL)-6 (20 ng/mL), IL-7 (20 ng/mL) (gifts
from Dr T. Sudo, Toray Industries, Kamakura, Japan), stem cell
factor (50 ng/mL) (a gift from Chemo-Sero-Therapeutic,
Kumamoto, Japan), and erythropoietin (EPO, 2 U/mL) (a gift from
Snow-Brand Milk Product, Tochigi, Japan) at 37°C in humidified
5%-CO2 air. The in vitro colony assay for hematopoietic
progenitors was performed in a methylcellulose-containing semisolid
medium as described previously.19
Quantitative analysis of vascular bed areas After CD31 immunohistochemical staining, images were integrated using a color chilled 3CCD camera (Hamamatsu Photonics, Shizuoka, Japan). Image-processing software (NIH image 1.62/Power Macintosh G3, National Institutes of Health, Bethesda, MD) was used to determine alterations in the size of vascular beds. Four vascular beds from each P-Sp explant were measured under different culture conditions. The values of all parameters are shown as the mean ± SD. P values were calculated by 2-tailed Student t test analysis.RT-PCR analysis RNA was extracted at E9.5 from P-Sp regions, yolk sacs, total embryos, and OP9 stromal cells using RNeasy Mini kit (Qiagen, Hilden, Germany). RNA was reverse transcribed using an Advantage RT-for-PCR Kit (Clontech, Palo Alto, CA). The complementary DNAs (cDNAs) were amplified with Advantage cDNA PCR Kit (Clontech) in a Gene AmpPCR System 9700 (Perkin-Elmer, Norwalk, CT) for 35 cycles. Sequences of specific primer for reverse transcription-polymerase chain reaction (RT-PCR) were as follows: VEGFR-1; sense: 5'-GAGAGCATCTATAAGGCAGCGGATT-3'; antisense: 5'-CACGTTTACAATGAGAGTGGCAGTG-3'; VEGFR-2; sense: 5'-TACACAATTCAGAGCGATGTGTGGT-3'; antisense: 5'-CTGGTTCCTCCAATGGGATATCTTC-3'; VEGFR-3; sense: 5'-AGATGCAGCCGGGCGCTGCGCT-3'; antisense: 5'-TAGGCTGTCCCCGGTGTCAATC-3'; VEGF-A; sense: 5'-AAGGAGAGCAGAAGTCCCATGAAGT-3'; antisense: 5'-TTCACATCTGCTGTGCTGTAGGAAG-3'; VEGF-C; sense: 5'-GCTTCTTGTCTCTGGCGTGTTC-3'; antisense: 5'-AAACTGATTGTGACTGGTTTGG-3';-actin; sense: 5'-TCGTGCGTGACATCAAAGAG-3'; antisense:
5'-TGGACAGTGAGGCCAAGATG-3'.
Each cycle consisted of 15 seconds of denaturation at 94°C and 3 minutes of annealing and extension at 68°C. PCR products were separated on a 1.5% agarose gel and stained with ethidium bromide.
Localization of VEGFR-2 and VEGFR-3 in early embryogenesis Although VEGFR-2 and VEGFR-3 are VEGF-C receptors, the distinct signaling pathways of VEGF-C through VEGFR-2 and VEGFR-3 have not been clarified. We first analyzed the expression pattern of VEGFR-2 and VEGFR-3 by whole-mount immunohistochemistry. A monoclonal antibody recognizing an endothelial marker, PECAM-1/CD31, was used to specifically visualize the vascular endothelium. The vascular network undergoes angiogenesis and remodeling to form a branched and intricate network in the head region of the E9.5 embryo (Figure 1A). We examined the expression pattern of VEGFR-2 using an anti-VEGFR-2 monoclonal antibody. VEGFR-2 was expressed in vascular endothelial cells (Figure 1B). VEGFR-3 expression was examined in whole-mount by LacZ staining using VEGFR-3+/LacZ mice at E9.5.18 VEGFR-3 expression was clearly visible in the major vessels of the trunk where VEGFR-2 was also expressed (Figure 1C). We further analyzed VEGFR-2 and VEGFR-3 expression by FACS analysis. Cells from VEGFR-3+/LacZ mice at E9.5 were stained with FACS-gal and labeled with monoclonal antibodies directed against VEGFR-2 and CD31 (Figure 1D). Consistent with the immunohistochemical staining, flow cytometric analyses revealed that VEGFR-2+VEGFR-3+ cells constituted a major proportion (71%) of the CD31+ fraction at E9.5. Approximately 13% and 8% of all cells expressed only VEGFR-2 or VEGFR-3, respectively.
Blood vessel defects in the yolk sac of a VEGFR-3-deficient embryo A VEGFR-3-deficient embryo at E9.5 was obviously pale compared with the wild type, allowing unequivocal identification of deficient mutants (Figure 2A-B). To determine the role of VEGFR-3 in vasculogenesis, we examined the vasculature of yolk sacs by immunohistochemical staining with the anti-CD31 antibody. The endothelial cells observed in the yolk sacs of VEGFR-3-deficient embryos expressed CD31 normally. However, we found abnormal vascular network formation and no caliber changes (Figure 2C-D). The main trunk of the vitelline artery was not seen in yolk sacs of VEGFR-3-deficient embryos (Figure 2A-B). Histologic examination of yolk sac sections (E9.5) revealed hematopoietic cells within normal blood vessels but few cells in the vessels of a VEGFR-3-deficient embryo (Figure 2E-F). The total cell number of blood cells from the yolk sacs in VEGFR-3-deficient mutants was reduced to 50% of controls (Figure 2G), and hematopoietic cells stained with May-Grünwald-Giemsa from a wild-type (Figure 2H) and a VEGFR-3-deficient (Figure 2I) embryo were revealed to be mature primitive erythroid cells, which were reactive to antiembryonic hemoglobin antibody (Figure 2J-K). Despite normal maturation of red blood cells, VEGFR-3-deficient embryos show marked anemia. To determine how development of primitive hematopoiesis is disturbed, we examined the colony-forming capacity of yolk sac cells of E9.5 VEGFR-3-deficient embryos. Erythroid and granulocyte-macrophage (GM) colony-forming cells (CFCs) did not show a significant difference (Table 1).
Development of definitive hematopoietic cells in VEGFR-3-deficient embryos VEGFR-3-deficient embryos display early embryonic lethality due to defects in the organization of large vessels prior to the emergence of lymphatic vessels.18 In addition, VEGFR-3-deficient embryos showed severe anemia (Figure 2A-B) and cardiac effusion, as reported by Dumont et al.18 Immunohistologic analysis of the embryo section showed abnormal vasculature and decreased numbers of blood cells in the dorsal aorta (data not shown).To examine definitive hematopoiesis of the VEGFR-3-deficient embryos,
we performed coculture of E9.5 P-Sp on OP9 stromal cells, which can
support hematopoietic cell development.19 After 10 days of
the culturing, we counted the total cell number per explant of P-Sp. It
was found that the cell number decreased to 15% of the wild-type and
heterozygous in VEGFR-3-homozygous mutant embryos, as described
below. Staining with May-Grünwald-Giemsa showed that the
blood cells from a VEGFR-3-deficient embryo contained very few
hematopoietic cells, including erythroblasts, mature neutrophils, and
macrophages (data not shown). CFCs in nonadherent cells were examined
in a methylcellulose medium. As shown in Table 2, the CFCs in P-Sp cells from
VEGFR-3-deficient embryos were not detected on days 7 and 10. Moreover, FACS analyses also revealed less than 50% of erythroid cells
(CD45+Ter119+ cells) in VEGFR-3-deficient
embryos (data not shown). These findings demonstrated that total cell
numbers of erythroid cells and definitive hematopoietic progenitors
deceased in the VEGFR-3-deficient embryos.
VEGF-C is a regulator in differentiation into both endothelial and hematopoietic cells We investigated VEGF-C signaling through VEGFR-2 and VEGFR-3 using a P-Sp explant coculture system with OP9 stromal cells. The formation of vascular beds and networks from P-Sp explants was observed (Figure 3A). Vascular beds are dense sheets of endothelial cells formed by proliferation of endothelial cells. Formation of a vascular bed in an explant is regarded as an indicator of vasculogenesis. Subsequent sprouting or branching of endothelial cells from vascular beds induced networks, a process similar to angiogenesis (Figure 3B). To investigate the endogenous expression of VEGFs and VEGFRs in this culture system, we examined the messenger RNA (mRNA) expression of VEGF-A, VEGF-C, and their specific receptors (VEGFR-1, VEGFR-2, and VEGFR-3) in P-Sp explants and OP9 stromal cells by RT-PCR. Messenger RNA encoding VEGFR-1, VEGFR-2, VEGFR-3, VEGF-A, and VEGF-C were detected in P-Sp explants, whereas VEGF-A mRNA was detected in OP9 cells (Figure 3C). We further histochemically examined the expression of VEGFR-2 and VEGFR-3 in the cultured vasculature of P-Sp. VEGFR-2 expression was clearly visible in a vascular bed and vascular networks, whereas VEGFR-3 expression was visualized only in a vascular bed (Figure 3D).
To clarify the effect of VEGF-A and VEGF-C, we added these factors to the culture of P-Sp explants. VEGF-A and VEGF-C enhanced the vascular bed formation but not the vascular network formation (Figure 3E). Quantitative analyses revealed that VEGF-A and VEGF-C evoked an increase in the area of the vascular bed dose-dependently (Figure 3F). On the other hand, VEGF-A and VEGF-C suppressed the generation of hematopoietic cells from P-Sp explants dose-dependently (Figure 3G). These results show that VEGF-C stimulates the vasculogenesis and suppresses the hematopoiesis in a dose-dependent manner like VEGF-A (Figure 3F-G). They also suggest that VEGF-C signaling through VEGFR-2 and VEGFR-3 is critical to the proliferation and differentiation of vascular endothelial cells and hematopoietic cells at an early embryonic stage. However, it is not clear whether the biologic function of VEGF-C is the same as that of VEGF-A; nor has it been shown whether VEGFR-2 and VEGFR-3 transduce the same signals upon binding to VEGF-C. VEGF-C rescued vascular bed formation of the P-Sp explants in the absence of VEGF-A To assay the function of VEGF-A and VEGF-C in P-Sp explants, we prepared chimeric proteins containing the extracellular domain of either VEGFR-1 or VEGFR-3, which contain the ligand binding site, fused to human IgG Fc (VEGFR-1-Fc and VEGFR-3-Fc). These soluble chimeric proteins function as competitors by binding their respective ligands and preventing them from binding to receptors. Addition of 20 µg/mL of VEGFR-1-Fc to explant cultures suppressed formation of vascular beds and networks compared with a control, 20 µg/mL of CD4-Fc (Figure 4A-B). By contrast, the formation of vascular beds and networks was unchanged by addition of 20 µg/mL of VEGFR-3-Fc (Figure 4A,C). In the presence of VEGFR-1-Fc, we next added VEGF-C to this P-Sp culture system. The addition of 100 ng/mL of VEGF-C rescued the formation of vascular beds completely but not vascular networks (Figure 4D), whereas VEGF-A rescued the formation of vascular beds and networks in a dose-dependent manner (Figure 4E-F). These results indicate that VEGF-C promotes independently the vascular bed formation through VEGFR-2 and VEGFR-3.
Enlarged vascular bed formation of P-Sp explants from VEGFR-3-deficient embryos To investigate the differences in VEGF-C signaling through VEGFR-2 and VEGFR-3, we examined vascular bed and network formation from P-Sp explants of VEGFR-3-deficient embryos. First, we confirmed the mRNA expression of VEGF-related genes and receptors in wild-type, heterozygous, and homozygous mutant embryos by RT-PCR. The expression of VEGFR-1, VEGFR-2, VEGF-A, and VEGF-C was unchanged in VEGFR-3 homozygote mutant embryos (Figure 5A).
Surprisingly, the vascular beds formed by P-Sp of the VEGFR-3 homozygous mutant embryos were larger than those seen in explants from wild-type and heterozygous mice (Figure 5Bi-iii). In quantitative analyses, the vascular bed from VEGFR-3 homozygous mutant mice was 2.5 times larger than that from control embryos (Figure 5C). VEGFR-2 expression was detected in vascular beds and networks of VEGFR-3-deficient mice (Figure 5Biv). Taking into consideration that VEGF-C signals transduce only through VEGFR-2 in VEGFR-3-deficient mice, these results suggest that VEGF-C signal-stimulated the vasculogenesis through VEGFR-2. To confirm this, VEGFR-3-Fc was added in this culture system. Formation of the vascular bed was significantly suppressed (Figure 5Bv,C), suggesting that VEGFR-3-Fc traps endogenous VEGF-C and decreases the signaling through VEGFR-2. Furthermore, exogenous VEGF-C enhanced the formation of vascular beds in VEGFR-3-deficient mice (Figure 5Bvi). On the other hand, addition of VEGFR-3-Fc significantly increased the number of hematopoietic cells generated from P-Sp of VEGFR-3-deficient mice (Figure 5D).
In this report, we show that VEGF-C signaling through VEGFR-2 and VEGFR-3 plays essential and distinct roles in embryonic vasculogenesis. First, we examined the expression of VEGFR-2 and VEGFR-3 in mouse embryos. Both receptors show similar immunohistochemical staining patterns on vascular endothelial cells of mouse embryos at E9.5. VEGFR-1 and VEGFR-2 expression is also restricted to the vascular endothelium.27,28 VEGFR-3 is expressed in the vascular endothelium during embryonic development and is subsequently restricted to lymphatic endothelium postnatally.13,16 These results show that the VEGFR-2 and VEGFR-3 expression pattern changes throughout the course of embryogenesis and suggest that both receptors are important for vasculoangiogenesis. FACS analysis showed that 71% of the CD31+ cells were positive for both VEGFR-2 and VEGFR-3. It is interesting to characterize VEGFR-2+ cells (13%) and VEGFR-3+ cells (8%). It is reported that VEGFR-3 is expressed in avian notochord at the gastrulation stage.29 VEGFR-2+VEGFR-3+ cells could potentially transduce both VEGF-A and VEGF-C signals. These results pose 2 questions: first, is the biologic function of VEGF-C equivalent to that of VEGF-A in these cells and, second, do VEGFR-2 and VEGFR-3 transduce the same VEGF-C signals to endothelial cells? We evaluated the effects of VEGFs on vasculoangiogenesis using mouse
embryonic P-Sp explants containing endothelial precursor cells
cocultured with OP9 stromal cells.19 We showed that
VEGFR-1, VEGFR-2, VEGFR-3, VEGF-A, and VEGF-C are all expressed in this system, although VEGF-A was detected in OP9 cells. This observation indicates that signaling through VEGFR-1, VEGFR-2, and VEGFR-3 potentially mediates endothelial cell growth in the culture system. Furthermore, we observed that VEGFR-2 was expressed in vascular beds
and networks, whereas VEGFR-3 was detected in vascular beds. These
results show that VEGFR-2 was expressed in all vascular endothelial
cells, but VEGFR-3 was restricted to proliferating endothelial cells.
In fact, exogenous VEGF-A or VEGF-C enhanced vascular bed formation
3-fold compared with controls. Consistent with this, it has been shown
that VEGF-A and VEGF-C promote differentiation of endothelial cells in
vitro in chick embryos.29,30 Our findings lead us to
several conclusions: (1) VEGF-A/VEGFR-2 is a primary signal of
endothelial proliferation, (2) VEGF-C/VEGFR-3 is also involved in
vasculogenesis and hematopoiesis and, finally, (3) the binding of
VEGF-C to VEGFR-3 regulates VEGFR-2 signaling. Taken together, they
suggest the model depicted in Figure 6.
Vascular bed and network formation is completely inhibited by addition of a soluble VEGFR-1-Fc chimeric protein to the coculture system, indicating that soluble VEGFR-1-Fc inhibits VEGF-A and VEGF-B binding to VEGFR-1 and VEGFR-2. Endogenous levels of VEGF-C are not sufficient to stimulate formation of vascular beds and networks in the presence of VEGFR-1-Fc. That VEGF-A plays an important role in vasculogenesis is supported by the finding that proliferation of endothelial cells is significantly inhibited in VEGF-A mutant embryos.9,10 Vascular bed and network formation is, however, normal in P-Sp cultures in the presence of VEGFR-3-Fc. Although VEGF-C and VEGF-D signaling is inhibited by VEGFR-3-Fc, VEGF-A signaling through VEGFR-1 and VEGFR-2 independently promotes vasculogenesis. Exogenous VEGF-C rescued vascular bed formation but not network formation in the presence of VEGFR-1-Fc, suggesting that VEGF-C promotes vasculogenesis but not angiogenesis. Even in VEGF-A mutant embryos, some endothelial cells survive,9 and that survival may be promoted by VEGF-C. We are interested in determining whether exogenous VEGF-C will rescue the VEGF-A-deficient phenotype. The vascular bed formed by VEGFR-3-deficient mice is 2.5 times larger than that formed by wild-type or VEGFR-3 heterozygous embryos in P-Sp culture. This finding is correlated with the phenotypes observed in VEGFR-3-deficient embryos. An immature pattern is seen in the perineural vascular plexus of the developing head region, and large vessels are disorganized with defective lumens.18 In addition, we noted the absence of the large vitelline artery. VEGF-C binding affinity is reported to be about 135 pM for VEGFR-3 and about 410 pM for VEGFR-2.12,31 Excessive VEGF-C signaling through VEGFR-2 may occur in P-Sp from VEGFR-3-deficient embryos because VEGFR-2 would be the sole receptor for VEGF-C. Through VEGFR-2, VEGF-C enhances vasculogenesis synergistically with VEGF-A. VEGFR-3 sequesters VEGF-C, thereby regulating VEGFR-2 signaling. In a similar context, Fong et al reported that VEGFR-1 regulates the amount of free VEGF-A available for vascular development.32 In the absence of VEGFR-1, there may be disregulation of the amount of free VEGF-A, leading to excessive development of hemangioblasts. Although there is no direct evidence that VEGF-C through VEGFR-2 enhances VEGF-A signaling, there is evidence to support our conclusion. Keyt et al showed that there are no homologous regions in the receptor binding sites of VEGF-C and VEGF-A.33 Furthermore, VEGF-C was shown to synergize with VEGF-A in the induction of angiogenesis in collagen gels.34 If VEGF-A and VEGF-C recognize the same binding site in VEGFR-2, these synergistic effects would not be seen. In VEGFR-2-deficient mice, VEGFR-3 expression is detectable by RT-PCR analysis.8 It is indicated that the VEGFR-3 signaling cannot replace the VEGFR-2 signaling during early embryogenesis. However, it is interesting to clarify whether exogenous VEGF-C can rescue the defect of VEGFR-2 knockout mice. We demonstrated that VEGFR-3 is essential for definitive hematopoietic cell proliferation. Hematopoiesis consists of primitive hematopoiesis in the yolk sac and definitive hematopoiesis, which develops in the P-Sp region, including the vitelline artery.35-37 Primitive hematopoietic cell numbers in the yolk sac of VEGFR-3-deficient mice were reduced, although their precursors did not decrease significantly. On the other hand, definitive hematopoiesis was profoundly suppressed in VEGFR-3-deficient embryos. Severe anemia may be a cause of their death in addition to cardiovascular abnormalities. Because the direct effect of VEGFs on hematopoiesis has not been reported, the defect in definitive hematopoiesis might be caused by vascular abnormalities, including defect of the vitelline artery between the embryo and yolk sac. Hematopoietic cells and endothelial cells are derived from common progenitor cells, hemangioblasts,38 which might be VEGFR-2+ and TIE-2+.39,40 It is not clear whether VEGFR-3 is involved at this level. Endothelial differentiation requires VEGFs, whereas hematopoietic differentiation proceeds in the absence of VEGFs.30 Similarly, we show that VEGF-C suppressed the definitive hematopoiesis and enhanced endothelial cell growth from P-Sp. The VEGFR-3-deficient embryo is a good model that shows abnormal vasculogenesis and suppressed hematopoiesis as a result. The anemia may be a secondary effect due to the defects in vascular cells that produce hematopoietic cytokines and growth factors (Figure 6). Here we have demonstrated that VEGF-C signaling through VEGFR-3 plays an important role in vasculogenesis and that the levels of free VEGF-C may be critical for this signaling. In addition, we have also shown that VEGF-C signaling through VEGFR-2 enhances VEGF-A activity. These findings may contribute to the development of new therapeutics for ischemic diseases.
The authors thank Dr O. Ohneda for valuable discussions and Hiroaki Kodama for providing us with OP9 stromal cells.
Submitted March 27, 2000; accepted August 3, 2000.
Supported by Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Toshio Suda, Department of Cell Differentiation, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Kumamoto 860-0811, Japan; e-mail: sudato{at}gpo.kumamoto-u.ac.jp.
1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674[Medline] [Order article via Infotrieve].
2.
Hanahan D.
Signaling vascular morphogenesis and maintenance.
Science.
1997;277:48-50
3.
Mustonen T, Alitalo K.
Endothelial receptor tyrosine kinases involved in angiogenesis.
J Cell Biol.
1995;129:895-898 4. Korpelainen EI, Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol. 1998;10:159-164[Medline] [Order article via Infotrieve].
5.
Gale NW, Yancopoulos GD.
Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.
Genes Dev.
1999;13:1055-1066 6. Breier G, Risau W. The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol. 1996;6:454-456[Medline] [Order article via Infotrieve]. 7. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 1995;376:66-70[Medline] [Order article via Infotrieve]. 8. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 1995;376:62-66[Medline] [Order article via Infotrieve]. 9. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439[Medline] [Order article via Infotrieve]. 10. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442[Medline] [Order article via Infotrieve].
11.
Olofsson B, Korpelainen E, Pepper MS, et al.
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells.
Proc Natl Acad Sci U S A.
1998;95:11709-11714 12. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290-298[Medline] [Order article via Infotrieve]. 13. Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development. 1996;122:3829-3837[Abstract].
14.
Achen MG, Jeltsch M, Kukk E, et al.
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).
Proc Natl Acad Sci U S A.
1998;95:548-553 15. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF- E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 1999;18:363-374[Medline] [Order article via Infotrieve].
16.
Kaipainen A, Korhonen J, Mustonen T, et al.
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.
Proc Natl Acad Sci U S A.
1995;92:3566-3570
17.
Jeltsch M, Kaipainen A, Joukov V, et al.
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.
Science.
1997;276:1423-1425
18.
Dumont DJ, Jussila L, Taipale J, et al.
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3.
Science.
1998;282:946-949 19. Takakura N, Huang XL, Naruse T, et al. Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity. 1998;9:677-686[Medline] [Order article via Infotrieve].
20.
Cao Y, Linden P, Farnebo J, et al.
Vascular endothelial growth factor C induces angiogenesis in vivo.
Proc Natl Acad Sci U S A.
1998;95:14389-14394 21. Kataoka H, Takakura N, Nishikawa S, et al. Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev Growth Differ. 1997;39:729-740[Medline] [Order article via Infotrieve]. 22. Pajusola K, Aprelikova O, Armstrong E, Morris S, Alitalo K. Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene. 1993;8:2931-2937[Medline] [Order article via Infotrieve].
23.
Hirashima M, Kataoka H, Nishikawa S, Matsuyoshi N, Nishikawa S.
Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis.
Blood.
1999;93:1253-1263
24.
Yano M, Iwama A, Nishio H, Suda J, Takada G, Suda T.
Expression and function of murine receptor tyrosine kinases, TIE and TEK, in hematopoietic stem cells.
Blood.
1997;89:4317-4326 25. MacGregor GR, Nolan GP, Fiering S, Roederer M, Herzenberg LA. Use of E. coli LacZ (beta-galactosidase) as a reporter gene. Methods Mol Biol. 1991;7:217-235.
26.
Nakano T, Kodama H, Honjo T.
Generation of lymphohematopoietic cells from embryonic stem cells in culture.
Science.
1994;265:1098-1101 27. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72:835-846[Medline] [Order article via Infotrieve]. 28. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn. 1995;203:80-92[Medline] [Order article via Infotrieve]. 29. Eichmann A, Corbel C, Jaffredo T, et al. Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. Development. 1998;125:743-752[Abstract].
30.
Eichmann A, Corbel C, Nataf V, Vaigot P, Breant C, Le Douarin NM.
Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2.
Proc Natl Acad Sci U S A.
1997;94:5141-5146 31. Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997;16:3898-3911[Medline] [Order article via Infotrieve]. 32. Fong GH, Zhang L, Bryce DM, Peng J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development. 1999;126:3015-3025[Abstract].
33.
Keyt BA, Nguyen HV, Berleau LT, et al.
Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors: generation of receptor-selective VEGF variants by site-directed mutagenesis.
J Biol Chem.
1996;271:5638-5646 34. Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol. 1998;177:439-452[Medline] [Order article via Infotrieve]. 35. Medvinsky AL, Samoylina NL, Muller AM, Dzierzak EA. An early pre-liver intraembryonic source of CFU-S in the developing mouse. Nature. 1993;364:64-67[Medline] [Order article via Infotrieve]. 36. Muller AM, Medvinsky A, Strouboulis J, Grosveld F, Dzierzak E. Development of hematopoietic stem cell activity in the mouse embryo. Immunity. 1994;1:291-301[Medline] [Order article via Infotrieve]. 37. Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell. 1996;86:897-906[Medline] [Order article via Infotrieve]. 38. Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature. 1997;386:488-493[Medline] [Order article via Infotrieve]. 39. Nishikawa SI, Nishikawa S, Kawamoto H, et al. In vitro generation of lymphohematopoietic cells from endothelial cells purified from murine embryos. Immunity. 1998;8:761-769[Medline] [Order article via Infotrieve].
40.
Hamaguchi I, Huang XL, Takakura N, et al.
In vitro hematopoietic and endothelial cell development from cells expressing TEK receptor in murine aorta-gonad-mesonephros region.
Blood.
1999;93:1549-1556
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. R. Swift and B. M. Weinstein Arterial-Venous Specification During Development Circ. Res., March 13, 2009; 104(5): 576 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Foster, S. C. Slater, J. Seckley, D. Kerjaschki, D. O. Bates, P. W. Mathieson, and S. C. Satchell Vascular Endothelial Growth Factor-C, a Potential Paracrine Regulator of Glomerular Permeability, Increases Glomerular Endothelial Cell Monolayer Integrity and Intracellular Calcium Am. J. Pathol., October 1, 2008; 173(4): 938 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Covassin, J. A. Villefranc, M. C. Kacergis, B. M. Weinstein, and N. D. Lawson Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish PNAS, April 25, 2006; 103(17): 6554 - 6559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tachibana, N. Jones, D. J. Dumont, M. C. Puri, and A. Bernstein Selective Role of a Distinct Tyrosine Residue on Tie2 in Heart Development and Early Hematopoiesis Mol. Cell. Biol., June 1, 2005; 25(11): 4693 - 4702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tammela, B. Enholm, K. Alitalo, and K. Paavonen The biology of vascular endothelial growth factors Cardiovasc Res, February 15, 2005; 65(3): 550 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferrari, M. Morini, U. Pfeffer, S. Minghelli, D. M. Noonan, and A. Albini Inhibition of Kaposi's Sarcoma in Vivo by Fenretinide Clin. Cancer Res., December 1, 2003; 9(16): 6020 - 6029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Eubank, M. Galloway, C. M. Montague, W. J. Waldman, and C. B. Marsh M-CSF Induces Vascular Endothelial Growth Factor Production and Angiogenic Activity From Human Monocytes J. Immunol., September 1, 2003; 171(5): 2637 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsumura, M. Hirashima, M. Ogawa, H. Kubo, H. Hisatsune, N. Kondo, S. Nishikawa, T. Chiba, and S.-I. Nishikawa Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3 Blood, February 15, 2003; 101(4): 1367 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hamada, Y. Oike, Y. Ito, H. Maekawa, K. Miyata, T. Shimomura, and T. Suda Distinct Roles of Ephrin-B2 Forward and EphB4 Reverse Signaling in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 190 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oike, Y. Ito, K. Hamada, X.-Q. Zhang, K. Miyata, F. Arai, T. Inada, K. Araki, N. Nakagata, M. Takeya, et al. Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells Blood, July 30, 2002; 100(4): 1326 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. STACKER, M. E. BALDWIN, and M. G. ACHEN The role of tumor lymphangiogenesis in metastatic spread FASEB J, July 1, 2002; 16(9): 922 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Jussila and K. Alitalo Vascular Growth Factors and Lymphangiogenesis Physiol Rev, July 1, 2002; 82(3): 673 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Witmer, J. Dai, H. A. Weich, G. F.J.M. Vrensen, and R. O. Schlingemann Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia J. Histochem. Cytochem., June 1, 2002; 50(6): 767 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Minehata, Y.-s. Mukouyama, T. Sekiguchi, T. Hara, and A. Miyajima Macrophage colony stimulating factor modulates the development of hematopoiesis by stimulating the differentiation of endothelial cells in the AGM region Blood, April 1, 2002; 99(7): 2360 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto and L. Claesson-Welsh VEGF Receptor Signal Transduction Sci. Signal., December 11, 2001; 2001(112): re21 - re21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Zhang, N. Takakura, Y. Oike, T. Inada, N. W. Gale, G. D. Yancopoulos, and T. Suda Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2+ endothelial cells Blood, August 15, 2001; 98(4): 1028 - 1037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kadambi, C. Mouta Carreira, C.-o. Yun, T. P. Padera, D. E. J. G. J. Dolmans, P. Carmeliet, D. Fukumura, and R. K. Jain Vascular Endothelial Growth Factor (VEGF)-C Differentially Affects Tumor Vascular Function and Leukocyte Recruitment: Role of VEGF-Receptor 2 and Host VEGF-A Cancer Res., March 1, 2001; 61(6): 2404 - 2408. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. J. Klasa, A. F. List, and B. D. Cheson Rational Approaches to Design of Therapeutics Targeting Molecular Markers Hematology, January 1, 2001; 2001(1): 443 - 462. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
), and VEGFR-3 homozygous mutant (